DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Perfromance Wealth Partners LLC

Perfromance Wealth Partners LLC boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,996 shares of the medical device company’s stock after purchasing an additional 1,420 shares during the quarter. Perfromance Wealth Partners LLC’s holdings in DexCom were worth $2,722,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. Versant Capital Management Inc acquired a new stake in DexCom in the 4th quarter valued at about $25,000. Riverview Trust Co grew its position in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in shares of DexCom during the third quarter worth approximately $57,000. Covestor Ltd boosted its holdings in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

DXCM has been the topic of a number of recent analyst reports. Sanford C. Bernstein lifted their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Citigroup upped their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Leerink Partners lowered their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada lowered their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.29.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Up 2.3 %

Shares of NASDAQ:DXCM opened at $86.32 on Wednesday. The business’s 50 day simple moving average is $78.46 and its two-hundred day simple moving average is $77.56. The firm has a market cap of $33.72 billion, a P/E ratio of 51.69, a PEG ratio of 2.21 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.